The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance

Abstract With the emergence of sodium-glucose cotransporter 2 inhibitors (SGLT2i), the treatment of type 2 diabetes mellitus (T2DM) has achieved a new milestone, of which the insulin-independent mechanism could produce weight loss, improve insulin resistance (IR) and exert other protective effects. Besides the well-acknowledged biochemical processes, the dysregulated balance between sympathetic and parasympathetic activity may play a significant role in IR and obesity. Weight loss caused by SGLT-2i could be achieved via activating the liver–brain–adipose neural axis in adipocytes. We previously demonstrated that SGLT-2 are widely expressed in central nervous system (CNS) tissues, and SGLT-2i could inhibit central areas associated with autonomic control through unidentified pathways, indicating that the role of the central sympathetic inhibition of SGLT-2i on blood pressure and weight loss. However, the exact pathway of SGLT2i related to these effects and to what extent it depends on the neural system are not fully understood. The evidence of how SGLT-2i interacts with the nervous system is worth exploring. Therefore, in this review, we will illustrate the potential neurological processes by which SGLT2i improves IR in skeletal muscle, liver, adipose tissue, and other insulin-target organs via the CNS and sympathetic nervous system/parasympathetic nervous system (SNS/PNS).

[1]  Ligang Zhou,et al.  The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors , 2022, Diabetes, metabolic syndrome and obesity : targets and therapy.

[2]  V. Matthews,et al.  Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition , 2022, Current Hypertension Reports.

[3]  H. Arima,et al.  Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice. , 2021, Journal of pharmacological sciences.

[4]  V. Bagnato,et al.  Carbon-Based Materials in Photodynamic and Photothermal Therapies Applied to Tumor Destruction , 2021, International journal of molecular sciences.

[5]  P. Borboni,et al.  Autonomic Nervous System in Obesity and Insulin-Resistance—The Complex Interplay between Leptin and Central Nervous System , 2021, International journal of molecular sciences.

[6]  Hiraku Ono,et al.  Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats , 2021, BMJ Open Diabetes Research & Care.

[7]  Xiongjie Shi,et al.  Inhibition of the sodium–glucose co‐transporter SGLT2 by canagliflozin ameliorates diet‐induced obesity by increasing intra‐adipose sympathetic innervation , 2021, British journal of pharmacology.

[8]  Lingli Zhang,et al.  Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy , 2021, Diabetes, metabolic syndrome and obesity : targets and therapy.

[9]  D. Vanderschueren,et al.  Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy , 2020, International journal of molecular sciences.

[10]  A. Magno,et al.  SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for Beiging , 2020, Biomedicines.

[11]  C. Moro,et al.  Novel Insights and Mechanisms of Lipotoxicity-Driven Insulin Resistance , 2020, International journal of molecular sciences.

[12]  Chaoxun Wang,et al.  Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice , 2020, Diabetes, metabolic syndrome and obesity : targets and therapy.

[13]  G. D'Agostino,et al.  Brain control of appetite during sickness , 2020, British journal of pharmacology.

[14]  E. Soliman,et al.  Insulin resistance and reduced cardiac autonomic function in older adults: the Atherosclerosis Risk in Communities study , 2020, BMC Cardiovascular Disorders.

[15]  W. Ogawa,et al.  Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor. , 2020, Endocrine journal.

[16]  A. Magno,et al.  SGLT2 Inhibitor–Induced Sympathoinhibition , 2020, JACC. Basic to translational science.

[17]  A. Vorotnikov,et al.  Latent Inflammation and Defect in Adipocyte Renewal as a Mechanism of Obesity-Associated Insulin Resistance , 2019, Biochemistry (Moscow).

[18]  N. Ward,et al.  SGLT2 Inhibitor–Induced Sympathoinhibition , 2019, JACC. Basic to translational science.

[19]  M. Blüher.  Obesity: global epidemiology and pathogenesis , 2019, Nature Reviews Endocrinology.

[20]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[21]  S. Atkin,et al.  Sodium–glucose cotransporter inhibitors and oxidative stress: An update , 2018, Journal of cellular physiology.

[22]  P. Moreira,et al.  Effects of weight changes in the autonomic nervous system: A systematic review and meta-analysis. , 2019, Clinical nutrition.

[23]  S. Goh,et al.  Weight loss associated with sodium‐glucose cotransporter‐2 inhibition: a review of evidence and underlying mechanisms , 2018, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[24]  M. Husain,et al.  Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA , 2018, Current Diabetes Reports.

[25]  M. Packer.  Do sodium‐glucose co‐transporter‐2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis , 2018, Diabetes, obesity & metabolism.

[26]  J. Rosenstock,et al.  Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET) , 2018, Diabetes, obesity & metabolism.

[27]  Yasushi Tanaka,et al.  Tofogliflozin decreases body fat mass and improves peripheral insulin resistance , 2018, Diabetes, obesity & metabolism.

[28]  Frank B. Hu,et al.  Global aetiology and epidemiology of type 2 diabetes mellitus and its complications , 2018, Nature Reviews Endocrinology.

[29]  L. Ji,et al.  The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta‐Analysis , 2018, Obesity.

[30]  T. Ota,et al.  Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization , 2017, Adipocyte.

[31]  E. Barroso,et al.  Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus , 2017, Trends in Endocrinology & Metabolism.

[32]  Y. Izumida,et al.  Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry. , 2017, Biochemical and biophysical research communications.

[33]  V. Matthews,et al.  Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2 , 2017, Journal of hypertension.

[34]  Yasushi Tanaka,et al.  Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes , 2017, Expert opinion on pharmacotherapy.

[35]  S. Andrikopoulos,et al.  Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity , 2017, Diabetes, obesity & metabolism.

[36]  J. Eriksson,et al.  Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year , 2017, Diabetes, obesity & metabolism.

[37]  S. Kaneko,et al.  SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice , 2017, EBioMedicine.

[38]  R. Eckel,et al.  Lipid Processing in the Brain: A Key Regulator of Systemic Metabolism , 2017, Front. Endocrinol..

[39]  L. Ji,et al.  Comparisons of weight changes between sodium‐glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment in type 2 diabetes patients: A meta‐analysis , 2017, Journal of diabetes investigation.

[40]  R. Printz,et al.  Correcting Postprandial Hyperglycemia in Zucker Diabetic Fatty Rats With an SGLT2 Inhibitor Restores Glucose Effectiveness in the Liver and Reduces Insulin Resistance in Skeletal Muscle , 2017, Diabetes.

[41]  C. Ballantyne,et al.  Skeletal muscle inflammation and insulin resistance in obesity , 2017, The Journal of clinical investigation.

[42]  N. Yahagi.  Hepatic Control of Energy Metabolism via the Autonomic Nervous System , 2017, Journal of atherosclerosis and thrombosis.

[43]  R. Aronson,et al.  Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis. , 2017, Diabetes technology & therapeutics.

[44]  E. Bonifacio,et al.  Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis , 2016, Diabetes.

[45]  S. Moon,et al.  Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes , 2016, PloS one.

[46]  S. Kaul,et al.  Temporal Changes in Skeletal Muscle Capillary Responses and Endothelial-Derived Vasodilators in Obesity-Related Insulin Resistance , 2016, Diabetes.

[47]  H. Miyoshi,et al.  Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. , 2016, Endocrine journal.

[48]  H. Katagiri,et al.  Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice , 2016, PloS one.

[49]  T. Kadowaki,et al.  Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice. , 2016, Endocrinology.

[50]  T. Pieber,et al.  Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes , 2016, Diabetes.

[51]  S. Tangvarasittichai.  Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. , 2015, World journal of diabetes.

[52]  E. Wright,et al.  Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences , 2015, Diabetes & vascular disease research.

[53]  A. Doria,et al.  Activation of human brown adipose tissue by a β3-adrenergic receptor agonist. , 2015, Cell metabolism.

[54]  J. Dixon,et al.  Sympathetic activity and markers of cardiovascular risk in nondiabetic severely obese patients: the effect of the initial 10% weight loss. , 2014, American journal of hypertension.

[55]  Lawrence A. Leiter,et al.  Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study , 2014, Diabetes Care.

[56]  R. DeFronzo,et al.  Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. , 2014, The Journal of clinical investigation.

[57]  J. Bolinder,et al.  Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin , 2014, Diabetes, obesity & metabolism.

[58]  H. Bays,et al.  Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus , 2013, Obesity.

[59]  R. Bergman,et al.  Variable Hepatic Insulin Clearance with Attendant Insulinemia is the Primary Determinant of Insulin Sensitivity in the Normal Dog , 2013, Obesity.

[60]  H. Pijl,et al.  A 5-Day High-Fat, High-Calorie Diet Impairs Insulin Sensitivity in Healthy, Young South Asian Men but Not in Caucasian Men , 2013, Diabetes.

[61]  Yongli Zhang,et al.  Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1/PI3K/Akt pathway. , 2013, International immunopharmacology.

[62]  K. Kataoka,et al.  Glycogen shortage during fasting triggers liver–brain–adipose neurocircuitry to facilitate fat utilization , 2013, Nature Communications.

[63]  M. J. Vazquez,et al.  Central melanin-concentrating hormone influences liver and adipose metabolism via specific hypothalamic nuclei and efferent autonomic/JNK1 pathways. , 2013, Gastroenterology.

[64]  H. Sell,et al.  Adaptive immunity in obesity and insulin resistance , 2012, Nature Reviews Endocrinology.

[65]  R. Bautista,et al.  Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats , 2012, Oxidative medicine and cellular longevity.

[66]  B. Goodpaster,et al.  Role of intramyocelluar lipids in human health , 2012, Trends in Endocrinology & Metabolism.

[67]  V. Woo,et al.  Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin , 2012, Annals of Internal Medicine.

[68]  E. Ferrannini,et al.  SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects , 2012, Nature Reviews Endocrinology.

[69]  M. Roden,et al.  The role of mitochondria in insulin resistance and type 2 diabetes mellitus , 2012, Nature Reviews Endocrinology.

[70]  John P H Wilding,et al.  Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial , 2012 .

[71]  E. Kraegen,et al.  Insulin resistance due to nutrient excess , 2011, Cell cycle.

[72]  H. Roche,et al.  Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue , 2011, Proceedings of the Nutrition Society.

[73]  R. DeFronzo,et al.  Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. , 2011, Endocrine reviews.

[74]  S. Aicher,et al.  Insulin acts in the arcuate nucleus to increase lumbar sympathetic nerve activity and baroreflex function in rats , 2011, The Journal of physiology.

[75]  E. Kraegen,et al.  Is it a consequence of AMPK downregulation , 2011 .

[76]  J. Feder,et al.  Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members , 2010, Diabetes therapy : research, treatment and education of diabetes and related disorders.

[77]  A. Kalsbeek,et al.  Hypothalamic control of energy metabolism via the autonomic nervous system , 2010, Annals of the New York Academy of Sciences.

[78]  E. Wright,et al.  Functional expression of SGLTs in rat brain. , 2010, American journal of physiology. Cell physiology.

[79]  Y. Shrestha,et al.  Sensory and sympathetic nervous system control of white adipose tissue lipolysis , 2010, Molecular and Cellular Endocrinology.

[80]  P. Strålfors,et al.  Attenuated mTOR Signaling and Enhanced Autophagy in Adipocytes from Obese Patients with Type 2 Diabetes , 2010, Molecular medicine.

[81]  Vicky Heath.  Differentiation: from α to β , 2010, Nature Reviews Endocrinology.

[82]  S. Julius,et al.  The complex interaction between overweight, hypertension, and sympathetic overactivity. , 2009, Journal of the American Society of Hypertension : JASH.

[83]  F. Kim,et al.  Hypothalamic leptin signaling regulates hepatic insulin sensitivity via a neurocircuit involving the vagus nerve. , 2009, Endocrinology.

[84]  M. Pfister,et al.  Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus , 2009, Clinical pharmacology and therapeutics.

[85]  J. Mariani,et al.  Blunted sympathetic neural response to oral glucose in obese subjects with the insulin-resistant metabolic syndrome. , 2009, The American journal of clinical nutrition.

[86]  H. Pijl,et al.  Intracerebroventricular Administration of Neuropeptide Y Induces Hepatic Insulin Resistance via Sympathetic Innervation , 2008, Diabetes.

[87]  M. Lazar,et al.  Central Resistin Induces Hepatic Insulin Resistance via Neuropeptide Y , 2007, The Journal of Neuroscience.

[88]  J. Elmquist,et al.  Serotonin 2C Receptor Agonists Improve Type 2 Diabetes via Melanocortin-4 Receptor Signaling Pathways , 2007, Cell metabolism.

[89]  Sib Sankar Roy,et al.  Molecular mechanism of insulin resistance , 2007, Journal of Biosciences.

[90]  A. Nishiyama,et al.  Aldosterone Suppresses Insulin Signaling Via the Downregulation of Insulin Receptor Substrate-1 in Vascular Smooth Muscle Cells , 2007, Hypertension.

[91]  H. Katagiri,et al.  Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity , 2006, Autonomic Neuroscience.

[92]  Olivier Boss,et al.  Serotonin Reciprocally Regulates Melanocortin Neurons to Modulate Food Intake , 2006, Neuron.

[93]  L. Lönn,et al.  Dysregulation of the autonomic nervous system can be a link between visceral adiposity and insulin resistance. , 2005, Obesity research.

[94]  G. Mancia,et al.  Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives , 2004, Journal of hypertension.

[95]  F. Luft,et al.  Aldosterone Potentiates Angiotensin II–Induced Signaling in Vascular Smooth Muscle Cells , 2004, Circulation.

[96]  F. Renström,et al.  In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo? , 2003, Metabolism: clinical and experimental.

[97]  M. Weiss,et al.  The paraventricular nucleus: an important component of the central neurocircuitry regulating sympathetic nerve outflow. , 2003, Acta physiologica Scandinavica.

[98]  M. Esler,et al.  Sympathetic nervous system and insulin resistance: from obesity to diabetes. , 2001, American journal of hypertension.

[99]  Y. Iwamoto,et al.  A possible involvement of parasympathetic neuropathy on insulin resistance in patients with type 2 diabetes. , 2001, Diabetes care.

[100]  S. Julius,et al.  Reflex sympathetic activation induces acute insulin resistance in the human forearm. , 1993, Hypertension.

[101]  P. Nestel,et al.  Noradrenaline turnover during under- and over-eating in normal weight subjects. , 1982, Metabolism: clinical and experimental.